London-based Sable Bio raised 3.75 million dollars in seed funding led by MMC Ventures to scale its...
The AMW Read
The article reports an incremental update for a new player in the AI drug safety sub-segment; the funding amount does not trigger cross.§D.
NoveltySignificance
Healthcare & Bio · Player Map
London-based Sable Bio raised 3.75 million dollars in seed funding led by MMC Ventures to scale its AI drug safety platform. With 0.5 million dollars in revenue and three top ten pharma partners, the startup targets the primary cause of clinical trial failure: toxicity. This shift toward predictive safety signals a systemic maturation of AI in biotech, moving beyond discovery to high-stakes de-risking. Automating these workflows will curb the billions lost annually to late-stage R&D attrition. 🚀 🧬